<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FD577585-992B-46A7-877C-1E29A9B5AC6F"><gtr:id>FD577585-992B-46A7-877C-1E29A9B5AC6F</gtr:id><gtr:name>Nanotether Discovery Science Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/131B05D2-9EE9-4044-8537-1B83833F9B09"><gtr:id>131B05D2-9EE9-4044-8537-1B83833F9B09</gtr:id><gtr:name>KWS Biotest</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/567CB79A-8B54-4422-A885-8E66ADBF592B"><gtr:id>567CB79A-8B54-4422-A885-8E66ADBF592B</gtr:id><gtr:name>AlgiPharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6E56A0E-DEC8-4190-8F26-42D643FBB0B8"><gtr:id>F6E56A0E-DEC8-4190-8F26-42D643FBB0B8</gtr:id><gtr:name>MBI (Wales) Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FD577585-992B-46A7-877C-1E29A9B5AC6F"><gtr:id>FD577585-992B-46A7-877C-1E29A9B5AC6F</gtr:id><gtr:name>Nanotether Discovery Science Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/131B05D2-9EE9-4044-8537-1B83833F9B09"><gtr:id>131B05D2-9EE9-4044-8537-1B83833F9B09</gtr:id><gtr:name>KWS Biotest</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/567CB79A-8B54-4422-A885-8E66ADBF592B"><gtr:id>567CB79A-8B54-4422-A885-8E66ADBF592B</gtr:id><gtr:name>AlgiPharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6E56A0E-DEC8-4190-8F26-42D643FBB0B8"><gtr:id>F6E56A0E-DEC8-4190-8F26-42D643FBB0B8</gtr:id><gtr:name>MBI (Wales) Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E8679824-FDB5-4146-9552-1FE7281A8ACF"><gtr:id>E8679824-FDB5-4146-9552-1FE7281A8ACF</gtr:id><gtr:firstName>Bryan</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G0900868"><gtr:id>A7EDF86D-716A-4C37-8325-1C2B70DFB2AF</gtr:id><gtr:title>DPFS Devolved Portfolio (Pilot)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G0900868</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3000897</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>KWS Biotest</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>KWS Biotest</gtr:description><gtr:id>6BA88219-BC14-449E-B160-2F80BB549245</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>DZF3H8XfcbR-1</gtr:outcomeId><gtr:partnerContribution>Boswellia extracts will be tested in an invivo model of colitis.</gtr:partnerContribution><gtr:piContribution>Boswellia extracts supplied for testing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Jones and Main, Queen Mary</gtr:description><gtr:id>4E9D0A4D-BCF0-4B44-9016-B275A916D290</gtr:id><gtr:impact>Gained EPSRC funding through the directed assembly network to develop the idea</gtr:impact><gtr:outcomeId>STnJV3CWmKL-1</gtr:outcomeId><gtr:partnerContribution>Expertise in repeat protein and fibres</gtr:partnerContribution><gtr:piContribution>Working on a project entitled - Directed protein fibre self-assembly through non-native amino acid incorporation and click chemistry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neuroscience</gtr:department><gtr:description>Boswellia Sheffield University</gtr:description><gtr:id>03F94962-5C6B-45A9-8E47-20758E1A7CC8</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>giHyaXbJjch-1</gtr:outcomeId><gtr:partnerContribution>Dr Andy Grierson is testing the Boswellia extract in an in vivo model of motor neurone disease</gtr:partnerContribution><gtr:piContribution>Extracts of Boswellia have been provided for testing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Jones and Stultz Southampton</gtr:description><gtr:id>0E4F79E4-3090-44B5-98D5-AAFD19F421A6</gtr:id><gtr:impact>EPSRC funding to develop proeject</gtr:impact><gtr:outcomeId>AEsEfqqLtb6-1</gtr:outcomeId><gtr:partnerContribution>Expertise in attachment of proteins and DNA origami</gtr:partnerContribution><gtr:piContribution>Working on project entitled Precision attachment of proteins in DNA origami tiles through click chemistry. 
Our expertise is in Click chemistry and protein enginneering</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Psychology</gtr:department><gtr:description>Cardiff and Bristol Neuroscience</gtr:description><gtr:id>479C62EA-7E5E-4DD7-96D8-56FAFB800F7C</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Qp2ZdzDrndt-1</gtr:outcomeId><gtr:partnerContribution>joint knowledge in methodology and techniques</gtr:partnerContribution><gtr:piContribution>Connecting a confirmed schizophrenia risk gene to neuronal, network and behavioural function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AlgiPharma</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>AlgiPharma - Ferguson</gtr:description><gtr:id>00BB4C26-6BC8-4029-BEA8-9E7E1E4B3488</gtr:id><gtr:impact>Production of innovative polymers. Two major applications for collaborative research in progress.</gtr:impact><gtr:outcomeId>DfC3AGD1nRg-1</gtr:outcomeId><gtr:partnerContribution>Fund the collaboration and supply polymers for research and testing</gtr:partnerContribution><gtr:piContribution>Testing of Polymers produced by the collaborator, Research and development testing conjugation properties</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GE Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Life Sciences</gtr:department><gtr:description>GE Healthcare</gtr:description><gtr:id>16FA0E94-44E7-4EFE-9EBD-FE7BE92AA731</gtr:id><gtr:impact>Research partnership</gtr:impact><gtr:outcomeId>PUHzB4v9kWH-1</gtr:outcomeId><gtr:partnerContribution>Use of their microscopy facilities</gtr:partnerContribution><gtr:piContribution>Expertise in viral infection and propogation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Janssen-Cilag</gtr:department><gtr:description>Janssen Pharmaceutica</gtr:description><gtr:id>8389FAE3-6162-441C-ADC0-C9F9A60AC5DC</gtr:id><gtr:impact>No outcome yet</gtr:impact><gtr:outcomeId>Fdam3itMAXE-1</gtr:outcomeId><gtr:partnerContribution>The collaboration will bring together the use of technology owned by the company with expertise from the academic research team. In addition to the money, a joint PhD studentship was awarded to work on both sites.</gtr:partnerContribution><gtr:piContribution>Academic expertise using unique methodology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>MRC-T TrkA Programme</gtr:description><gtr:id>E7088441-AADF-4AC5-89AB-7C8D03CEF964</gtr:id><gtr:impact>No outcomes yet.</gtr:impact><gtr:outcomeId>oKjbrNruLf2-1</gtr:outcomeId><gtr:partnerContribution>Collaboration will add value to the devolved portfolio funding project by running HTS, assays and medicinial chemistry guidance thus strengthening the capabilities of the funded research team.</gtr:partnerContribution><gtr:piContribution>Advice on target of interest (TrkA) and discussions around go/no go decisions; joint project management.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK Manchester Institute</gtr:department><gtr:description>VanSel Study CRT</gtr:description><gtr:id>B59B082A-144F-4DA3-8B9D-9EB329F7FACF</gtr:id><gtr:impact>This multicentre clinical trial is being set up by CRT and will commence in early 2012.</gtr:impact><gtr:outcomeId>ojX3CuTvPFs-1</gtr:outcomeId><gtr:piContribution>Our contribution to this Phase I trial will be to analyse the expression and phosphorylation of tumour biopsy samples provided using the CB1000 machine that was funded with the devolved portfolio award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nanotether Discovery Science Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nanotether Discovery Science with Dafydd Jones</gtr:description><gtr:id>42A941A0-DC06-4008-B16D-13570CE27771</gtr:id><gtr:impact>Novel protein kinase variants have been made for use as research tools on the project.</gtr:impact><gtr:outcomeId>bchZw9QDtCL-1</gtr:outcomeId><gtr:partnerContribution>NDS have funded the collaboration and are active in consultations and exchanges of staff, materials and expertise.</gtr:partnerContribution><gtr:piContribution>Ongoing collaboration related to site-specific post-translational modification of proteins (protein kinases specifically) with auxiliary molecules with the aim of high-throughput protein interaction screening. The approach uses genetically encoded azido chemistry incorporated into a target protein at a site amenable to post-translational modification without adversely effecting protein function using bioorthongonal Click Chemistry approaches. The collaboration involves consultations and exchanges of staff, materials and expertise with regards to non-natural amino acid incorporation into proteins and the subsequent Click Chemistry modification of proteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biochemistry Bristol</gtr:department><gtr:description>Jones and Collinson, Bristol</gtr:description><gtr:id>56B7EBC8-8D21-4983-8E71-BC5A6976C9DF</gtr:id><gtr:impact>Submitted a grant application for a joint PhD studentship</gtr:impact><gtr:outcomeId>kPuTKfquAjR-1</gtr:outcomeId><gtr:partnerContribution>Expertise in membrane proteins</gtr:partnerContribution><gtr:piContribution>Expertise in non-natural amino acid insorporation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Compton Group - Department of Chemistry</gtr:description><gtr:id>C58A0927-DF6A-4ADE-8AD4-F130097B142A</gtr:id><gtr:impact>The tests funded by SARTRE were carried out to test the anti-inflammatory properties of extracts of Boswellia frereana, commonly known as Somali frankincense,
in a murine model of acute Sodium Dextran Sulphate - induced colitis inflammation. Over a period of 7 days the plant extract significantly reduced the clinical symptoms associated with colitis related inflammation, such as loss in body weight, clinical scores and stool scores when compared to the saline control group. 
After day 8 the Boswellia frereana extract continued to have a significant effect on body weight loss and colon shortening whilst no significant effect was observed for the clinical and stool scores compared to the saline control group.
 
This promising data assisted The Compton Group in out licensing the patent application to an American group, which is led by the Head of Research and Development of a pharmaceutical company which has a market capitalisation of approximately US $ 25 billion. The present state of play is that the American group and Compton Group are 
organising the manufacture and clinical testing of 50,000 nutraceutical capsules with Boswellia frereana as the main ingredient.
 

Should the IP generate revenue, a royalty will be payable back to Cardiff University 

IP jointly owned 
Multidisciplinary collaboration - Ahmed Ali provides chemistry expertise, Academic team have biology expertise.</gtr:impact><gtr:outcomeId>iDtFZ2JVkxx-1</gtr:outcomeId><gtr:partnerContribution>In kind contribution of Ahmed Ali full time</gtr:partnerContribution><gtr:piContribution>The research team bring the biology and arthritis model expertise. Ahmed Ali works at the University woth use of all facilities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Chemistry</gtr:department><gtr:description>University of Southampton with Dafydd Jones</gtr:description><gtr:id>207026A6-015C-4964-B8AA-E3827C2FC785</gtr:id><gtr:impact>Knowledge sharing and exchange of ideas. 
Development of novel research tools</gtr:impact><gtr:outcomeId>RYFQt2JecM1-1</gtr:outcomeId><gtr:partnerContribution>Input on DNA origami approach and molecular assembly processes.</gtr:partnerContribution><gtr:piContribution>Site specific conjugation of proteins to DNA. The approach uses genetically encoded azido chemistry incorporated into a target protein at a site amenable to modification with DNA. The approach uses bioorthonganol Click Chemistry approaches. The ultimate aim is to control protein position and orientation in &amp;quot;DNA origami&amp;quot; based molecular assembly processes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Dentistry</gtr:department><gtr:description>Boswellia, Dental School</gtr:description><gtr:id>179C2EA6-3763-4260-893B-2F9A97B145D2</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>HDaU5bzxQnp-1</gtr:outcomeId><gtr:partnerContribution>Boswellia extracts are being tested in an invivo model of peridontal disease</gtr:partnerContribution><gtr:piContribution>Boswellia extracts supplied for testing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Honorary Research Fellow visiting from pharmaceutical industry</gtr:description><gtr:id>135BF76E-B0EA-4152-AB83-73ACAF6464E4</gtr:id><gtr:impact>Recent collaboration</gtr:impact><gtr:outcomeId>dymrEQKFHiv-1</gtr:outcomeId><gtr:partnerContribution>Has strengthened the links between academia and industry</gtr:partnerContribution><gtr:piContribution>The Visiting Fellow will advise SARTRE and associated academics on potential partnerships and collaborations</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MBI (Wales) Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MBI Wales</gtr:description><gtr:id>17884502-E0E8-49D3-BDD3-54C7E1FC5540</gtr:id><gtr:impact>MBI Wales have a Formal option agreement with Cardiff University to License and manufacture the sensor following clinical trials. 
This is a multidisciplinary collaboration involving microbiology, engineering and materials science.</gtr:impact><gtr:outcomeId>e91BAzsmL8m-1</gtr:outcomeId><gtr:partnerContribution>MBI have contributed to the development of the sensor, the development of the silicone based sensor, machining and production of sensors for testing. 
MBI Wales are also producing and supplying the sensors free of cost for clinical trials.</gtr:partnerContribution><gtr:piContribution>Have developed the sensor in collaboration. We have also contributed the microbiological expertise and in vitro testing.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Small Molecules Discovery Unit</gtr:department><gtr:description>MRCT - Calpain inhibitor project</gtr:description><gtr:id>FC51D509-B721-4C09-AD1B-50DC68A6AE6E</gtr:id><gtr:impact>Fluorescent inhibitor analogue produced for use in competitive screening assay. Preliminary data produced with the aim of applying for a collaborative grant to develop clinical candidate for treatment of rheumatoid arthritis.
Disciplines include inflammation biology, animal models of arthritis and synthetic and medicinal chemistry.</gtr:impact><gtr:outcomeId>MuqkUmdCArS-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise and medicinal chemistry input - advanced screening and development. Feasibility studies and follow up screening carried out.</gtr:partnerContribution><gtr:piContribution>Provision of expertise, research materials (protein and mercaptoacrylate inhibitors) and animal models of arthritis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bristol Urological Institute</gtr:department><gtr:description>Bristol Urological Institute</gtr:description><gtr:id>C2A5600B-567B-4292-A50D-2EDE1689BF15</gtr:id><gtr:impact>MHRA approval for the trial</gtr:impact><gtr:outcomeId>WRrmcdrq7Fv-1</gtr:outcomeId><gtr:partnerContribution>BUI are carrying out a clinical trial with the Catheter Encrustation sensors</gtr:partnerContribution><gtr:piContribution>We have devloped the sensors which are now entering alinical trials at BUI</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press Story on Cannabis and Schizophrenia - Matt Jones</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B50EC2C-22F9-4DA5-BC17-70688AA25E84</gtr:id><gtr:impact>Lots of media attention as the result of a paper showing that cannabis disrupts brain connectivity in a similar way to that seen in schizophrenia.

Articles published in many national newspapers including, The Times, The Daily Mail , The Sun and news websites worldwide. The fill list is below with links where available:

Health Day News - US News and World report http://health.usnews.com/health-news/familyhealth/brain-and-behavior/articles/2011/10/25/pot-can-mimic-brain-changes-seen-in-schizophrenia
Live Science http://www.livescience.com/16716-marijuana-schizophrenia-brain.html
National News London 
The Times 
El Mundo http://www.elmundo.es/elmundosalud/2011/10/25/neurociencia/1319567670.html
Nu.NL 
NRC Handelsblad (Dutch Newspaper) 
Australian Broadcasting Corportation 
Daily Mail http://www.dailymail.co.uk/health/article-2053486/One-cannabis-joint-bring-schizophrenia.html
Big German wire service 
Service of Science News and Information, (Madrid)
Metro International, world's largest global free daily newspaper http://www.metronews.ca/winnipeg/world/article/1006150--pot-use-knocks-the-orchestra-in-your-head-out-of-tune-study
Press Association http://www.google.com/hostednews/ukpress/article/ALeqM5i3HK6el6_l-NZ-VF5_AlDqpcclEg?docId=N0272841319557869122A
LA Times 
Gizmodo Australia http://www.gizmodo.com.au/2011/10/inside-your-brain-on-cannabis-cognitive-chaos/
Wired.com
http://www.wired.com/wiredscience/2011/10/marijuana-brain-chaos/
International Business Times Australia
http://au.ibtimes.com/articles/237667/20111026/cannabis-schizophrenic-marijuana-matt-jones-university-of-bristol-disorchestrated-michal-kucewicz.htm
The Independent online
http://www.independent.co.uk/life-style/health-and-families/health-news/cannabis-causes-chaos-in-the-brain-2376068.html
MSN http://news.uk.msn.com/health/articles.aspx?cp-documentid=159585354
Yahoo News http://uk.news.yahoo.com/cannabis-disrupts-brain-waves-222420787.html
Scinexx http://www.scinexx.de/wissen-aktuell-14038-2011-10-26.html
ABC http://www.abc.es/20111026/sociedad/abci-cannabis-201110260001.html
Ecoticias 
Europa Press http://www.europapress.es/salud/noticia-cannabis-podria-causar-especie-caos-cognitivo-cerebro-20111026101926.html
Scotsman
http://www.scotsman.com/news/health/cannabis_throws_brainwaves_into_chaos_1_1929411
New Kerala http://www.newkerala.com/news/2011/worldnews-94885.html
The Sun 
Le Figaro 
Fox News http://www.foxnews.com/health/2011/10/26/cannabis-disrupts-brain-waves-like-schizophrenia-study-finds/
CBS News http://www.cbsnews.com/8301-205_162-20125822/solved-why-pot-smoking-causes-memory-loss/
New Scientist Mag - page 5</gtr:impact><gtr:outcomeId>AqmcJmfSXPF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Ambitions event at University of West of England</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D6328004-785C-4BDF-A608-DA8556E8EB4E</gtr:id><gtr:impact>The event involved interactive discussions about science and novel therapeutics.

None yet known</gtr:impact><gtr:outcomeId>boSbUGvqdm1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Fellows Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE755D17-5098-4FA9-81AE-2DED40A2F162</gtr:id><gtr:impact>Presentation at Annual MRC Fellows' Symposium

Peer discussion</gtr:impact><gtr:outcomeId>mzN6Zn86QG8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>One Nucleus</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57E8959C-3732-439B-9A61-8C93CB8C22A1</gtr:id><gtr:impact>Presentation in London to promote novel collaborative models between industry, academia and health providers.

Follow-up discussions</gtr:impact><gtr:outcomeId>JRKaUxUASh8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wales Gene Park 6th form conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E83B8949-82C4-444B-A563-A04AD99DFE1D</gtr:id><gtr:impact>Talk about synthetic biology to around 1500 6th form students at St David's Centre in Cardiff,

Enthusiastic feedback received from particpating schools.</gtr:impact><gtr:outcomeId>LQPX9vN7uH7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press story Ahmed Ali Boswellia</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B64816C-9E4A-4DDF-B19C-05E20783CEF0</gtr:id><gtr:impact>In addition to the positive UK press / media coverage of this research the Somalia / Somaliland online press also gave positive coverage on this discovery with headlines such as &amp;quot;Somaliland Born Scientist finds a possible cure for arthritis using Somali frankincense&amp;quot;

Articles publsihed in The Somaliland Press and Somali Diaspora News</gtr:impact><gtr:outcomeId>jieZzxkwtSF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit BGS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AF179C0E-FEDC-4F67-A527-2B40D5871187</gtr:id><gtr:impact>Two events, one presentation to school groups; second as a guest at the science prize giving to the whole school.

Impact is to raise awareness of physical science and nanotechnology and how we can use it.</gtr:impact><gtr:outcomeId>cKuDvBSu64y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TEDx at Bristol Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>314138BD-B7FE-4F3E-ABA9-8D77D6F940F5</gtr:id><gtr:impact>TEDx brings together creative thinkers and innovators. These live presentations are also available on the World Wide Web so audience figures are potentially global.

This event had the theme of &amp;quot;the world around us&amp;quot; and the presentation was on the huge potential of nanotechnology to transform many aspects of our lives.</gtr:impact><gtr:outcomeId>PYd1Tq7R3yT</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BioWales 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95AEEEBE-D54F-4C78-913F-6FC0DACAF0AE</gtr:id><gtr:impact>Regional forum for biotech in Wales. Presented SARTRE and novel collaboration models with private sector

Follow-up discussions</gtr:impact><gtr:outcomeId>gNnwKe71uDr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Cafe, Synthetic Biology,  Dafydd Jones</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>30C1E4E0-CFA6-409F-A1D5-29630AB8015E</gtr:id><gtr:impact>Around 45 members of the public attended the Science Cafe. at the Gate Arts Centre Cafe. The evening event included an informal lay presentation of research in Synthetic Biology followed by questions and discussion with the audience.

The audience were very keen to participate in the discussion afterwards and enjoyed the event.</gtr:impact><gtr:outcomeId>KTDvHnKHSn4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation for Black History Month</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ACA9AB2C-953C-4E3F-ABC0-F3BCDB6D4289</gtr:id><gtr:impact>Oral presentation at Cardiff City hall, in support of Black History Month, with the underlying theme being about 'Somali History and their contribution to Wales'. 



Ahmed Ali was asked to represent Cardiff's Somali community and to discuss how Science in Wales is helping both communities. He showed them some of the data produced on the anti-arthritic properties of Somali frankincense and the audience both Somali and Welsh truly appreciated the positive contribution of this research.</gtr:impact><gtr:outcomeId>ptH8pkDYhFw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Wells</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1CE4AAA-BEE4-42D5-AD81-31240D535F2D</gtr:id><gtr:impact>presented and discussed nanoscience to Wells Science and Engineering Club

Impact is to raise awareness of physical science and nanotechnology and how we can use it.</gtr:impact><gtr:outcomeId>Fq3SWPqCxhG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press story Emma Blain Boswellia</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6EB1275F-05A9-4C39-99BC-22B685EF605F</gtr:id><gtr:impact>Press release which spraked considerable interest and was followed up by visit from a reporter, an interview and photo session for the local newspapers.

Full page article published in the Western Mail, article in South Wales Echo with pictures and a short article in The Daily Mail.
The story also appeared on news websites around the world.</gtr:impact><gtr:outcomeId>rPxsjEZoW9d</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Careers Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C7E74B4-A8BF-4432-9183-5B8774F7BF77</gtr:id><gtr:impact>Oral presentation on careers given to year 12 students

unknown</gtr:impact><gtr:outcomeId>BCx96jzc8pr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Technologies in Translational Research and Development Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1B3CCA57-1EC4-44A4-B4F4-FE7D7FFCCBF7</gtr:id><gtr:impact>Translational Research and Devlopment Event - One day meeting with a mixed audience including academic, commercial, government, nhs and technology transfer professionals.

Has not yet taken place</gtr:impact><gtr:outcomeId>Zq4S2aFZND6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>iSolve Project</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E06537B9-F665-49A5-8500-64DB6C56422D</gtr:id><gtr:impact>The iSolve involves a group of students looking at the commercialisation possibilities of a real research project and presenting to an audience of Local business representatives, entrepreneurs and students

The group won 1st prize. Impacts include involving students in commercialisation and stimulating the entreneurial and innovation culture within the University and encouraging contact with industry.</gtr:impact><gtr:outcomeId>mKeRqx4SW6V</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mediwales University Challenge Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1A524CFE-7123-42AD-A1F5-28D46EF149E8</gtr:id><gtr:impact>Presentation on translational research in Universities to audience mostly from local industry and Welsh government.

Engagement with local industry</gtr:impact><gtr:outcomeId>qa4erLTtRkp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Directed Assembly Network 2</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>94DC7816-8F79-44FB-86BE-61A47A7AECC9</gtr:id><gtr:outcomeId>ry2BcrRPjYL</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53928</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NISCHR PhD Studentship</gtr:description><gtr:fundingOrg>Health and Care Research Wales</gtr:fundingOrg><gtr:id>B3D6BB5A-7B70-414C-B5B9-80F4FB7D75D5</gtr:id><gtr:outcomeId>Bcgn7bPZ7Ey0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chairman's Award</gtr:description><gtr:fundingOrg>Cardiff and Vale University Health Board</gtr:fundingOrg><gtr:id>424A4B67-851D-4380-9943-43C57482D98D</gtr:id><gtr:outcomeId>VjqHKjwrZP90</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140473</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A4B</gtr:description><gtr:fundingOrg>Health and Care Research Wales</gtr:fundingOrg><gtr:id>779F5D4D-1C09-48B0-AD84-1FA6B2D94986</gtr:id><gtr:outcomeId>CFDuseP9PSH0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Social Fund</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>3618B241-58E9-40D3-8F39-F3D2F7E98077</gtr:id><gtr:outcomeId>AC68skKe2YY0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>109401</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Dunhill Medical Trust</gtr:description><gtr:fundingOrg>The Dunhill Medical Trust</gtr:fundingOrg><gtr:id>03A932F5-61FE-4943-86B7-B2E636DB06FB</gtr:id><gtr:outcomeId>BusTo7swdR10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Directed assembly network grant</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>13D7ACED-EE77-41DB-A8A6-12C0BECC0A60</gtr:id><gtr:outcomeId>oFGT78eeFz7</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49838</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust ISSF</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8A6E476F-0967-4685-B405-2573A9DEFCC3</gtr:id><gtr:outcomeId>fkUfKJw9Aic</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>980500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Programme Grant</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/12/6/29670</gtr:fundingRef><gtr:id>969BD1D8-2AED-45F1-8FA6-6D79D7C9AB2E</gtr:id><gtr:outcomeId>ehSmTvfopjB</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Value in People Award</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>AF46FA46-C157-4C67-AF3D-9D2F3094D512</gtr:id><gtr:outcomeId>hbaUbYnWRut0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BE6E0AD2-271C-4917-800F-9AC87E617DA4</gtr:id><gtr:outcomeId>ERKJ3Hg4Jwy0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DB84B75A-FA6D-43D1-A646-6E6F5E331840</gtr:id><gtr:outcomeId>YfunaXp864t</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Doctoral Prize Fellowship</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>7D6D9112-2DAC-4F10-B9B4-54C71D0F6EBF</gtr:id><gtr:outcomeId>oMkWXpiPjg1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>429787</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS Resources- A Core Protein Production Facility</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>ED9B6904-0ADD-4B35-A599-EA4264051F07</gtr:id><gtr:outcomeId>c56Ydx82nzd0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Non-Clinical Fellowship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3414E5EA-ED14-4C9C-A3B8-17A3E833865C</gtr:id><gtr:outcomeId>ku4eax5LG9i0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>138516</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Imaging Post - Senior Lectureship</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Health and Care Research Wales</gtr:fundingOrg><gtr:id>6FFFAC91-5F08-4F00-AC69-734E2B1C50E8</gtr:id><gtr:outcomeId>kmqLWpraUY80</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS Devolved Portfolio</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>03BB954D-0B75-4F96-9E13-89801DBE483B</gtr:id><gtr:outcomeId>btG3cTTs9Fj0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BRACE Charity funding</gtr:description><gtr:fundingOrg>BRACE (Alzheimer's disease charity)</gtr:fundingOrg><gtr:id>6BEBF26F-4751-4678-8A3C-BDA108691A26</gtr:id><gtr:outcomeId>YbGN7wy39VD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>635000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Astra-Zeneca</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9543BBBF-0112-4518-B414-9A77ADC0858D</gtr:id><gtr:outcomeId>aSYaKWfV1Wk</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ser Cymru National Research Network PhD studentship</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:id>B3B61CA3-43D5-4237-940D-35102F0D7EBE</gtr:id><gtr:outcomeId>B9gDbReoMLj</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wales Clinical Academic Track Fellowship</gtr:description><gtr:fundingOrg>Health and Care Research Wales</gtr:fundingOrg><gtr:id>CB48BDFA-910A-4A8B-B05A-622EBC0BDF12</gtr:id><gtr:outcomeId>Bv9rn8b8qyv0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>455618</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Project Grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/J015318/1</gtr:fundingRef><gtr:id>82A36602-D006-4527-B79E-980CE0F0E122</gtr:id><gtr:outcomeId>J8ys3JDb9HQ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18088</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Spark with Impact award</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>AE3331DC-D020-42D2-97C6-387364EB607A</gtr:id><gtr:outcomeId>S6SRM8qWeTa</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Extracts of Boswellia Frereana inhibit inflammation</gtr:description><gtr:grantRef>MC_G0900868</gtr:grantRef><gtr:id>44F80249-6E24-44E4-8F49-41F6E8B22591</gtr:id><gtr:impact>Commercial discussion are in progress with a number of commercial organisations and the material has been supplied to collaborators for in vivo tests (See Collaborations and Partnership)</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>Vd5E6r9hGa2</gtr:outcomeId><gtr:patentId>WO2011010080</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>INHIBITOR OF INFLAMMATORY CONDITIONS</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel dextrin-colistin conjugates which target colistin to the site of inflammation increasing therapeutic effect and decreasing systemic toxicity.</gtr:description><gtr:grantRef>MC_G0900868</gtr:grantRef><gtr:id>F0010E32-59F2-444E-93A6-D391909555AF</gtr:id><gtr:impact>Has provided the basis for applications for funding to progress to clinical studies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>aGz4oXtmoe2</gtr:outcomeId><gtr:patentId>WO2012035310</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic Conjugates</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Development of a University Research Institute for Health</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>E1C66079-FB1F-4460-A0F0-0CABD4004ED6</gtr:id><gtr:outcomeId>MwjLMEqEvnz</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>&amp;quot;Dysfunction of frontal cortices and their interactions with connected brain regions underpins overlapping cognitive impairments in an array of disorders including schizophrenia, ADHD, autism, Parkinson's disease, fronto-temporal dementia and Alzheimer's Disease. However, the extent to which similar behavioural abnormalities arise from common neural causes across this range of disorders remains unknown, limiting the scope for precise diagnoses and subsequent targeted treatments. As an entry point to this fundamental problem we will focus on response inhibition, a core component of frontal functioning, and combine behavioural testing in the Stop Signal Reaction Time Task with electrophysiological recordings in both human and mouse models with the aim of establishing sensitive and selective translational measures of frontal cortical function and dysfunction. These informative biomarkers have the potential to make an important contribution to accurate and consistent diagnoses and development of therapies targeted according to defined individual cognitive phenotypes in patients. 

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>B47A5374-637D-4AE0-B164-3738951B1910</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>KXTA2Bts3Hp</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>The neurophysiological basis of response inhibition and its use in diagnosis of complex frontal cortical dysfunction</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have developed a biosensor that in an in vitro bladder model consistently predicts catheter blockage, 24 h before it occurs. Whilst the sensor successfully indicates impending blockage, its performance can be enhanced by modification of its surface topography. The aim of this study is to generate a range of biosensors of different surface roughness and compare their relative performance to predict catheter encrustation. Optimal sensors will then be produced by injection moulding methods and confirmed to retain their high performance.

Most recent work supported by DPFS Portfolio Award 
Now in Clinical trials supported by the Chairman's Award from Cardiff and Vale NHS and the Bristol Urological Institute</gtr:description><gtr:id>7D2DA092-C2D2-460C-A136-659E99963231</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>GjGg3CfqpuE</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Detection of impending catheter blockage</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;The project will allow mechanical sensor techniques to be developed for the clinical environment as a practical improvement on conventional ELISA tests. It will give clinicians easy and immediate access to information about possible sepsis and its severity in patients allowing immediate response, dramatically increasing the prognosis. The project is based on the integration of new developments in mechanical sensor production and detection, where several of our own innovations in nanosensor instrumentation combined with recent research will facilitate optimization of the nanosensors for applications in liquids to the level necessary that even detection of prion infection in blood samples seems to be achievable. The goal of the project is to develop a proof-of-concept device that can be taken to a product that provides a new rapid diagnostic tool at the point of care.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>A7F5D038-EC07-4754-B922-2D3DC23EDD07</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>ibhgBYqppFv</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Diagnostic Probe Array Sensors for Sepsis and Blood Screening</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Nerve growth factor (NGF) is a key mediator in neuropathic and inflammatory pain. We have shown that sequestration of NGF abrogates pain in many conditions. Antagonism of the NGF/TrkA (tyrosine kinase receptor A) interaction will have similar benefits, and we have identified and validated the NGF binding domain of TrkA (TrkAIg2) as a target. We identified different classes of TrkA antagonists in silico; which have been confirmed in vitro. One compound was used for the rational design and synthesis of a series of low molecular weight, high affinity compounds. We have identified residues on the isolated TrkAIg2 which interact with compounds tested using protein nuclear magnetic resonance (NMR) analysis. Our established interdisciplinary team has expertise in biochemistry, NMR, molecular modelling, synthetic chemistry and in vivo validation. We plan to develop these compounds further towards entry into clinical trials as moderators of intractable pain states such as osteoarthritis and post-operative pain

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>FC6281EF-84F3-43FA-A141-651F47CE6470</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>qMiB9rssrbS</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Small molecule antagonists at the TrkA receptor for the treament of pain</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;This project will develop IP based on our discovery of a new method of drug delivery for the safe administration of antibiotics, currently rendered unusable due to toxicity issues. This programme will generate a library of antibiotic conjugates engineered for use in distinct human disease processes where Gram-negative antimicrobial resistance represents a major clinical challenge (cystic fibrosis and skin wounds). The conjugates will be optimised in a series of in vitro studies (including physicochemical characterisation and microbiological assays). The delivery system offers the opportunity to effectively target the antibiotic, which, following systemic administration, selectively accumulates at sites of inflammation and infection. This phenomenon effectively reduces the toxicity and increases the bioavailability of the antibacterial peptide. Seedcorn funding will develop and characterise these antibiotic conjugates to enhance the IP potential of the research prior to clinical testing and full-scale commercial development.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>17C58BCF-5D6B-4D7E-8143-24D6DF861B1D</gtr:id><gtr:impact>The patent covering this work has been enhanced by this activity and will be published and the end of Dec 2011.
Protocols for in vivo studies for efficacy and safety have been prepared and studies are due to start Dec 2011.</gtr:impact><gtr:outcomeId>jPgALTmasTv</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Bioresponsive polymer-peptide conjugates as novel antibacterial agents</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;In human cadavers a correlation exists between vertebral artery diameter and hypertension: narrower arteries-higher blood pressure. The question raised is whether the hypertension caused this narrowing or whether the narrowing (and reduced blood flow) caused the hypertension. In a hypertensive animal model, this re-modelling was also found but, interestingly, occurred before the hypertension. This supports our hypothesis that stenosed vertebral arteries, and subsequent poor perfusion of the brainstem, is a cause for hypertension. We wish to: (i) confirm the observations in living hypertensive man that there is a narrowing of cerebral vessels using magnetic resonance angiography (MRA) and, (ii) assess the prevalence of this condition and (iii) establish whether antihypertensive medication reverses cerebral artery stenosis. This study may have prognostic value and provide improved treatment regimes for hypertension, which is an escalating health issue since the numbers of those becoming resistant to drug treatment is ~25%.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>59F1B611-DA57-4647-897F-730BE9758552</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>CiCpBN44rxT</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Human hypertension and cerebral artery stenosis</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Protein therapeutics are a lucrative product stream for the pharmaceutical industry. To tackle some of their inherant problems (e.g. poor stability, short shelf-life, antigenic side-effects and poor pharmacokinetics), protein therapuetics are routinely derivatised posttranslationally with chemical entities such a polyethylene glycol (PEG). The drawback of PEGylation is that its effects on protein function are unpredictable. The problem is exacerbated by the fact that introduction of the PEG molecule on the protein is typically performed at a protein terminus or randomly on the protein surface. To address these issues, a novel proprietary protein mutagenesis tool will be used together with an expanded genetic code to incorporate unnatural amino acids into proteins at defined positions during cellular protein synthesis. The new chemistry inherent in the unnatural amino acid will allow protein modification by PEG at a specific position in a defined way so that both stability and bioactivity are maximised.
Novel variants of Keratinocyte Growth Factor have been developed. 
Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>E37D69FB-845A-4CA6-BEC8-F5415C80273C</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>BLVGS6AuXFm</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Enhanced protein therapuetics by optimisation of site specific post-translational derivatisation.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;This project utilises a reverse translation approach to develop and validate a novel approach to anxiety research. I have extensive experience of working in research groups that cross clinical and pre-clinical studies into psychiatric disorders. My PhD and subsequent research were undertaken in the Psychopharmacology Unit, Bristol with Prof Nutt and my fellowship enabled me to work the Cambridge Behavioural and Clinical Neuroscience Institute in Experimental Psychology in Cambridge. Using this background I have been able to develop a model that has the potential to detect a core symptom of anxiety disorders, negative affective state. Having used reverse translation to develop this approach, we now propose to take this model back into humans thus enabling us to take this strategy from bedside to bench and back again. This project will combine our model development with a second, translational method, the use of CO2- inhalation to induce anxiety.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>C5055D56-9AC8-45C0-B8AC-B11753708795</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>jYqzGWPqEab</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Development and validation of translational approaches to facilitate neurobiological and therapeutic advances in anxiety research.</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Over-impulsive behaviour is a feature of many neurological and psychiatric disorders, e.g., patients treated with dopamine agonists (20%) or deep brain stimulation for Parkinson's, Tourette's, mania, obsessive compulsive disorder, autism, schizophrenia and Huntington's disease. Such over-impulsivity results in serious consequences for patients including pathological gambling and even suicide. Seemingly similar impulsive behaviour across patients may be caused by diverse neuropathology, requiring different treatments. Currently clinicians rely on questionnaires and clinical interview to identify impulsivity and the neurobiological basis of the behaviour is not addressed. For development of targeted treatment, one must first have a tool that both accurately characterises the cognitive subsystem damaged and quantifies the degree of impairment. Currently no such objective test exists. We plan to develop a computerised cognitive task as a tool for measuring and characterising impulsivity in patients. Such a tool could be applied to treatment trials and during clinical assessment. 

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>04974BD9-0C40-47B8-81B9-AE92AAF268C3</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>rUSSmLevdXN</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Tool for the assessment of impulsivity</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Articular cartilage degradation is a classical feature of degenerative and inflammatory arthritides. The incidence of osteoarthritis (OA) is more prevalent in our ageing and increasingly obese population (1); current therapeutic strategies provide some pain relief, but adverse side effects make these less than desirable for chronic conditions. Identifying other potential pharmaceutical agents which can alleviate the symptoms associated with OA, whilst remaining efficacious and non-toxic, is an ongoing pursuit. Previously, we have demonstrated that treatment of cytokine-stimulated cartilage explants with Boswellia frereana - a novel Frankincence species, inhibited breakdown of the collagenous matrix, reduced MMP levels and significantly reduced nitric oxide, prostaglandin E2 and cycloxygenase-2 production. Epi-lupeol was identified as the principal constituent of B. frereana. We have now optimised the dose of B. frereana required to inhibit cytokine-induced degradation and determined that the active constituent is epi-lupeol. 

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>F49B4A8F-05FA-4487-BDCF-4CC3165DBEBC</gtr:id><gtr:impact>The Bowellia frereana extract have now been supplied to several partners for in vivo testing. See Collaboration and Partnership</gtr:impact><gtr:outcomeId>Le6kawwxM56</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Testing the efficacy of Boswellia frereana (Frankincence) as a nutraceutical for Osteoarthritis.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This proposal seeks funding to develop in house leads against metastatic colorectal cancer (MCRC), using modern medicinal chemistry, molecular modelling, and genetically defined invasive tumours arising autocthanously in transgenic mice. Using our established ProTide platform for the intracellular delivery of bioactive nucleotides, a 2nd generation family of agents related to the 1st generation MCRC drug thymectacin has been prepared. The funding will support the use of medicinal chemistry methods to develop these hits towards leads, aided by extensive local support and expertise particularly in the provision of appropriate transgenic mice and other sophisticated in vivo models of clinical relevance. Molecular modelling methodologies such as docking and 3D-QSAR, and exploiting the local high performance computing and visualisation facility will aid rational candidate selection. We will use our established in house high field multi-nuclear NMR-based screens for plasma stability, acid stability (for oral dosing), and metabolism in target and non-target tissue as potential predictors of in vivo exposure and efficacy/potency. The successful transitioning of leads tto early development will be established through potential license deals and/or research collaboration with leading commercial partners in the field, following business models that have been successful in these laboratories.
70 New chemical entities (protides) have been sythesised and tested to select lead compounds for animal testing
Most recent work supported by DPFS Portfolio Award</gtr:description><gtr:id>32D27FDB-64A3-47AD-B6AD-DE64EF1B2086</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>LA6TBp4Tjh2</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New agents for colorectal cancer  (CRC) using genetically defined autochthonous models</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;With a greater understanding of the processes involved in inflammatory disease, &amp;quot;&amp;quot;biologics&amp;quot;&amp;quot; such as anti-cytokine antibody can be a useful therapy. There are problems however, including their high cost: the need for intravenous infusions: and the high specificity of the antibody which limits their usefulness to diseases in which the targeted cytokine is the &amp;quot;&amp;quot;driver&amp;quot;&amp;quot; or rate limiting step. Our approach however aims (i) to inhibit a rate limiting step common to inflammatory cell extravasation (regardless of the cytokines &amp;quot;&amp;quot;drivers&amp;quot;&amp;quot;) by (ii) producing a small molecule inhibitor which can be taken orally. Our approach aims to inhibit the enzyme underlying the white cell morphology change (&amp;quot;spreading&amp;quot; onto the endothelium), namely the intracellular enzyme calpain-1, From knowledge of the structure of the novel Ca2+ binding site on calpain-1, blocking molecules are being designed. We are therefore synthesising compounds which target activation of this enzyme. We already have a novel calpain-1 inhibitor at least 10 times more potent that others reported to date.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>65BA91FC-A4B1-49E3-B8F7-80810343EAC1</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>RLFMQD9CUJE</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Calpain-1  small molecule inhibitors for anti-inflammatory therapy</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;We have discovered bicyclic pyrimidine nucleoside analogues (BCNAs): a new family of antiviral agents, with potent and selective action against Varicella Zoster Virus (VZV). BCNAs, designed and developed in Cardiff have entered clinical trial for shingles. Structural modification to generate dideoxy BCNA (ddBCNA) analogues leads to a loss of anti-VZV activity but the surprising introduction of selective activity against human cytomegalovirus (HCMV). The early lead compounds cf1821 and cf2095 are equi-active with the established HCMV drug ganciclovir. We have found novel L-enantiomers of these agents (cf2642) have enhanced antiviral activity against vaccinia virus, showing a potential for treatment of (small)poxvirus infections. These compounds appear to act via a novel mechanism, at viral entry, and share no cross-resistance with current agents. Given the unmet medical need of HCMV, the bioterror interests in (small)pox, and novelty of new compounds they represent new and promising leads for drug discovery. We will use our virology expertise to further optimize the lead compounds for antiviral activity, taking advantage of their UV fluorescence to track their cell entry.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>BD36DABF-6198-43D7-89DE-DCFBC5FBC5DC</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>ZMKQNxoxaqK</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Antiviral agents for the treatment of human cytomegalovirus and poxvirus infections</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>&amp;quot;Predicting tumour response and survival benefit to chemotherapy in individual patients is an increasingly important aspect of cancer therapy. This is particularly the case for the orally available EGF receptor tyrosine kinase inhibitors erlotinib/Tarceva and gefitinib/Iressa in the treatment of non-small cell lung cancers. This proposal will build on our observation that only a fraction of EGFR-positive tumours exhibit elevated EGFR signalling activity, and our prediction that only these patients will respond to inhibitor therapy. In this proposal we plan to adapt and optimise the tissue collection and protein detection methodology (focussing on a new, quantitative and exquisitely sensitive technology) such that we can measure EGFR signalling activity in samples obtained during routine clinical diagnosis. The methodology will then be used in a feasibility study of EGFR signalling in patients enrolled in an erlotinib trial. This will provide the data necessary to secure substantial follow-on funding to undertake a fully powered multicentre prospective clinical trial aimed at testing our central hypothesis, and so deliver a validated companion diagnostic for routine clinical practice. This has the potential to improve patient care and clinical outcomes, and also to allow significant cost savings to the NHS and other health care providers.

Most recent work supported by DPFS Portfolio Award&amp;quot;</gtr:description><gtr:id>AEDD06D2-C3DB-462E-9DD7-994E7773ADFA</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>sAy9hoBmvYj</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Quantitative analysis of EGFR signalling in lung cancer: improving prediction of tumour response and patient survival</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Custom Access database to log compound generations and associated data to progress development</gtr:description><gtr:id>BA9894FA-C986-4560-BBF3-E06451C3232D</gtr:id><gtr:impact>none yet known</gtr:impact><gtr:outcomeId>tL1orNcEk8E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Compound generation database</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Fluorscently labelled calpain inhibitor for use in competitive binding assay</gtr:description><gtr:id>255C546B-0F35-4EF6-9E24-8F5A4F25B6C4</gtr:id><gtr:impact>synthesised in Nov 2011 so none as yet.</gtr:impact><gtr:outcomeId>AsGUJTRYgXm</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Labelled Calpain inhibitor</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>System for screening in-frame TAG mutations (introduction of the amber stop codon for orthogonal incorportaion of non-natural amino-acids) using a GFP (green fluorescent protein) based approach.</gtr:description><gtr:id>B1550E1A-D471-41E5-A2A1-A6BF50AFDCF9</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>KqoYxSCKNHT</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>System for screening in-frame TAG mutations</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Unique methodology of combined electrophysiology and mouse SSRTT</gtr:description><gtr:id>B9307279-6026-4AD4-93D3-521E7B73BCEB</gtr:id><gtr:impact>Joint funding from MRC project grant in order to collaborate</gtr:impact><gtr:outcomeId>FTkLEFhz8zB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mouse model of SSRTT</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines: mammalian cell lines with relevant receptors expressed stably: hTrkA, rodent TrkA, hTrkB, hTrkC, hp75.</gtr:description><gtr:id>EB8FEE68-F7AF-489B-94A0-C3AD3FDBB4B0</gtr:id><gtr:impact>Material is required for SAR assays and other aspects of programme</gtr:impact><gtr:outcomeId>fjrESWAbsZD</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human Trk cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Several new variants of GFP - Green fluorescent protein containing azide groups which can be modified by light. Light induced modification by photolysis has been demonstrated including in cells for confocal imaging. These have great potential for high resolution imaging and wider implication in terms of optpgenetics.</gtr:description><gtr:id>59234FD6-DD3A-41FC-85FC-7BEB57C6AE4A</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>kFMsEKNkdxz</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Azide containing GFP variants</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6F8C1906-F296-465C-A947-453820B75311</gtr:id><gtr:title>In Vitro and In Vivo Recording of Local Field Potential Oscillations in Mouse Hippocampus.</gtr:title><gtr:parentPublicationTitle>Current protocols in mouse biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b42f445d4a11bece176c13c2d44652"><gtr:id>b2b42f445d4a11bece176c13c2d44652</gtr:id><gtr:otherNames>Forsyth LH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2161-2617</gtr:issn><gtr:outcomeId>ZNmf2oNeCot</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A686EBE3-9115-478D-8FA2-679347F32281</gtr:id><gtr:title>Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link?</gtr:title><gtr:parentPublicationTitle>Current hypertension reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16cb1bf605db85569bd50abd911753ca"><gtr:id>16cb1bf605db85569bd50abd911753ca</gtr:id><gtr:otherNames>Cates MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1522-6417</gtr:issn><gtr:outcomeId>pm_14779_29_22562144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CAD47DC-12C0-481D-B9AE-D708077A6F4F</gtr:id><gtr:title>Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain.</gtr:title><gtr:parentPublicationTitle>Pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/141c69a42bb75f57d91cfe6e9dd239da"><gtr:id>141c69a42bb75f57d91cfe6e9dd239da</gtr:id><gtr:otherNames>McNamee KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0304-3959</gtr:issn><gtr:outcomeId>gGWTtV4oKa7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51BB1DAE-CF68-48E5-95B2-F956E1E8FE27</gtr:id><gtr:title>Colistin in burn intensive care: back to the future?</gtr:title><gtr:parentPublicationTitle>Burns : journal of the International Society for Burn Injuries</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f97458871cf40b5ebf7e0994f2a37ab8"><gtr:id>f97458871cf40b5ebf7e0994f2a37ab8</gtr:id><gtr:otherNames>Azzopardi EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-4179</gtr:issn><gtr:outcomeId>pm_14779_29_22871554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD7B55D-CBE1-488E-B05A-C76E56A4AD27</gtr:id><gtr:title>Novel antiviral activity of l-dideoxy bicyclic nucleoside analogues versus vaccinia and measles viruses in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21ea743c0b8ec2c794e384c67efc5506"><gtr:id>21ea743c0b8ec2c794e384c67efc5506</gtr:id><gtr:otherNames>McGuigan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14779_29_23320521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9195DA23-1061-402E-A692-6EE6C2392614</gtr:id><gtr:title>Colistin past and future: a bibliographic analysis.</gtr:title><gtr:parentPublicationTitle>Journal of critical care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f97458871cf40b5ebf7e0994f2a37ab8"><gtr:id>f97458871cf40b5ebf7e0994f2a37ab8</gtr:id><gtr:otherNames>Azzopardi EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0883-9441</gtr:issn><gtr:outcomeId>pm_14779_29_22762926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8B416F8-EF64-433F-9147-BAFD02BB7373</gtr:id><gtr:title>The enhanced permeability retention effect: a new paradigm for drug targeting in infection.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f97458871cf40b5ebf7e0994f2a37ab8"><gtr:id>f97458871cf40b5ebf7e0994f2a37ab8</gtr:id><gtr:otherNames>Azzopardi EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14779_29_23054997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25890DCC-5AD4-4839-8509-291D998618A7</gtr:id><gtr:title>Genetically encoding phenyl azide chemistry: new uses and ideas for classical biochemistry.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f837068fb6456823898b13025b6f2188"><gtr:id>f837068fb6456823898b13025b6f2188</gtr:id><gtr:otherNames>Reddington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_14779_29_24059505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C625BA7-D903-44DA-A8CA-C0177F3AB5ED</gtr:id><gtr:title>Ca&amp;sup2;? and calpain control membrane expansion during the rapid cell spreading of neutrophils.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f01a6abcb36928cadcd14051ddd2410"><gtr:id>6f01a6abcb36928cadcd14051ddd2410</gtr:id><gtr:otherNames>Dewitt S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_14779_29_23943875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E50CF32D-0286-4056-AF86-6EA64641664D</gtr:id><gtr:title>Aryl azide photochemistry in defined protein environments.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48c06dadc1f2050f11f237341e562b6c"><gtr:id>48c06dadc1f2050f11f237341e562b6c</gtr:id><gtr:otherNames>Morris JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>pm_14779_29_23351055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AAA52B6-CF62-4D20-85A5-28EA6F6B7D8C</gtr:id><gtr:title>Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16d3ebac32c726ba4724b6a5a709d964"><gtr:id>16d3ebac32c726ba4724b6a5a709d964</gtr:id><gtr:otherNames>Coulthard EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14779_29_23114368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2243F75-F193-472D-A05E-37E1A23BBB32</gtr:id><gtr:title>Residue choice defines efficiency and influence of bioorthogonal protein modification via genetically encoded strain promoted Click chemistry.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af2a2f12e586e77d6699ff438039d030"><gtr:id>af2a2f12e586e77d6699ff438039d030</gtr:id><gtr:otherNames>Reddington SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>pm_14779_29_22801454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>522450A2-F732-48B7-A93E-AEF8A3EC7554</gtr:id><gtr:title>Transposon-based approaches for generating novel molecular diversity during directed evolution.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b9b0bf6a5043fb43a25ad564ede62d"><gtr:id>c8b9b0bf6a5043fb43a25ad564ede62d</gtr:id><gtr:otherNames>Jones DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>1064-3745</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>aDCih3p9sc1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D61F2FBE-6330-4A14-8AEB-8A0FD55371A7</gtr:id><gtr:title>Potent inhibition of Ca
 
 -dependent activation of calpain-1 by novel mercaptoacrylates</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d5ca3e7fb4665839f6fab3cfc3300b2"><gtr:id>1d5ca3e7fb4665839f6fab3cfc3300b2</gtr:id><gtr:otherNames>Adams S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>NXDuyXZy1pH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>004B02EC-7DF5-41CF-9915-FC0DBE30C82A</gtr:id><gtr:title>Different photochemical events of a genetically encoded phenyl azide define and modulate GFP fluorescence.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af2a2f12e586e77d6699ff438039d030"><gtr:id>af2a2f12e586e77d6699ff438039d030</gtr:id><gtr:otherNames>Reddington SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>pm_14779_29_23620472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08CB3051-70C1-4801-99AA-30DE266F925D</gtr:id><gtr:title>Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage.</gtr:title><gtr:parentPublicationTitle>Phytotherapy research : PTR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c59687617f36cccea1c5d5285923931e"><gtr:id>c59687617f36cccea1c5d5285923931e</gtr:id><gtr:otherNames>Blain EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0951-418X</gtr:issn><gtr:outcomeId>oqceRjSXuLA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BDD23C9-509C-4195-BA47-6AC0E5EEF1C7</gtr:id><gtr:title>Ca2+ activation of cytosolic calpain induces the transition from apoptosis to necrosis in neutrophils with externalized phosphatidylserine.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a022acce0e845b22b591216b863ab56c"><gtr:id>a022acce0e845b22b591216b863ab56c</gtr:id><gtr:otherNames>Francis RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_14779_29_23089743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4621EC2F-0938-456F-95D4-0CFE0B146D22</gtr:id><gtr:title>Development of an &amp;quot;early warning&amp;quot; sensor for encrustation of urinary catheters following Proteus infection.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part B, Applied biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29f66f0297e49c4160fb566ffcec2072"><gtr:id>29f66f0297e49c4160fb566ffcec2072</gtr:id><gtr:otherNames>Malic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4973</gtr:issn><gtr:outcomeId>UCpow5d443p</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G0900868</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>